Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammation
Biotech
Rebranded NodThera plans IPO to fund NLRP3 inhibitor program
NodThera—under its new name Rezera—is planning an IPO as the biotech steps up its ambitions to get its NLRP3 inhibitor to market.
James Waldron
Oct 22, 2026 5:27am
Roche signs $1B Dualitas deal to collab on bispecific screening
Sep 17, 2026 8:07am
CEO O’Day tells Fierce how Gilead reached ‘critical mass’
Sep 16, 2026 8:00am
Teva autoimmune antibody notches ph. 2 win in celiac disease
Sep 2, 2026 10:52am
TScan’s strategy unaffected by Amgen scrapping $500M+ collab
Aug 19, 2026 5:31pm
Regeneron ends eye disease trial following safety review
Aug 17, 2026 2:30pm